When I started at Regeneron, the space I worked in had a name that sounded much nicer than it actually was. It was called the Skybox, and it was not a corner office. It was a work trailer built on risers in the warehouse above the loading dock.And when trucks backed in, my desk would shake. You could feel the doors rolling up and the pallets moving beneath you. Rain, wind, snow, it didn't matter.The skybox was a building inside the building, sealed off from the outside world, except for the rumble of the fr ...

Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. https://t.co/hXH82cdSkd ...

Alzheimer’s drugs that target the buildup of the amyloid protein on the brain don’t meaningfully help patients, a major review found, raising questions about medicines developed by the likes of Eli Lilly and Eisai https://t.co/Om1hCYCbjL ...

INSIGHT: $BIO is today's top trending coin amid news of Eli Lilly’s acquisition of startup Crossbridge Bio. https://t.co/oKgAG07kKh ...

Suntory Holdings is set to acquire Daiichi Sankyo Healthcare, the over-the-counter pharmaceuticals subsidiary of Daiichi Sankyo, the Nikkei newspaper reports https://t.co/NtPKs0FHlo ...

From Makers Of Weight-Loss Pills To Anti-Wrinkle Shots, Meet South Korea’s Lab-Grown Billionaires https://t.co/N2vzWM9TGWIllustration: Hidayat via Adobe Firefly https://t.co/GSOoDoeApN ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who bought Aquestive securities between June 16, 2025, and January 8, 2026, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - Rosen Law Firm has a strong history in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its performance in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - The GLP-1 market is highly competitive, with Novo Nordisk and Eli Lilly as key players, each offering different products and pricing strategies to capture market share. Group 1: Product Offerings and Pricing - Novo Nordisk has launched a higher dose version of Wegovy in the US, priced at $399 for cash customers and about $25 for those with insurance, undercutting Eli Lilly's Zepbound by approximately $100 [1] - Eli Lilly's Zepbound and Mounjaro are viewed as market leaders due to their efficacy, with tirzepatide (Zepbound) being considered the most effective product currently available [4][5] - Novo Nordisk has also introduced a pill version of its product, expected to be available in 2026, expanding its range of injectables [2] Group 2: Market Dynamics and Competition - Efficacy is the primary driver of market share, with Zepbound currently holding a superior position unless a product demonstrates significantly increased effectiveness [5][6] - Eli Lilly is seen as having a strong pipeline of future products, including retatrutide, which may offer higher weight loss percentages and cater to more extreme cases [7][8] - As competition increases, prices are expected to decline, leading to higher demand, particularly among cash-paying consumers who are more price-sensitive [10][12] Group 3: Company Outlooks - Eli Lilly is on a positive outlook due to its growth story, investments in manufacturing and R&D, and improving balance sheet [14][15] - Novo Nordisk is currently rated with a stable outlook, having started with lower leverage compared to Eli Lilly [16] - The injectables are expected to remain the primary treatment method, despite the introduction of pill forms, as they are more effective and have established usage among diabetes patients [18][19] Group 4: Future Developments - Other pharmaceutical companies, such as Amgen and Pfizer, are entering the GLP-1 market with products that may require less frequent dosing, although none currently appear to surpass Zepbound in effectiveness [21][22][23]

Eli Lilly’s Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company said. https://t.co/oS1ZE59Ng7 ...

The flood of cheap copies of Novo Nordisk's Ozempic in India is already reshaping the country’s fast-growing obesity market https://t.co/2gSCRrxStR ...